AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
企業コードAIM
会社名AIM ImmunoTech Inc
上場日Jul 12, 1996
最高経営責任者「CEO」Mr. Thomas K. Equels, Esq., J.D.
従業員数21
証券種類Ordinary Share
決算期末Jul 12
本社所在地2117 Sw Highway 484
都市OCALA
証券取引所NYSE American Consolidated
国United States of America
郵便番号32801
電話番号13524487797
ウェブサイトhttps://aimimmuno.com/
企業コードAIM
上場日Jul 12, 1996
最高経営責任者「CEO」Mr. Thomas K. Equels, Esq., J.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし